Catechol-O-methyltransferase, a new target for pancreatic cancer therapy

    loading  Checking for direct PDF access through Ovid


Catechol-O-methyltransferase (COMT) is an important molecule in different types of cancers. Its biological effect and therapeutic significance, however, rarely been investigated fully in pancreatic cancer. Immunohistologically, high COMT expression was significantly correlated with the longer overall survival of patients (P< 0.05), indicating its protective nature. The effects of COMT on cell growth, apoptosis, and invasion were evaluated using overexpression and silencing methods. In detail, we carried out experiments using one stably transduced and two transiently transfected pancreatic cancer cell linesin vitro, and one stably transduced cell linein vivo mice xenograft models.In vitro experiments showed that COMT inhibited cell proliferation, enhanced gemcitabine-induced apoptosis, and inhibited cell invasion in stably transduced and transiently transfected cell lines by regulating the PI3K/Akt pathway, p53, and E-cadherin. The COMT overexpressed and silenced cell lines showed significantly inhibited and enhanced growth capacities inin vivo xenograft models, respectively. In conclusion, COMT suppressed pancreatic cancer and its high expression predicted longer survival time. The interaction of COMT with the PI3K/Akt pathway makes it a potential target for therapy.

Catechol-O-methyltransferase (COMT) serves as a tumor-suppressor for pancreatic cancer. Higher COMT levels in the surgical specimens predict longer survival. COMT also inhibits pancreatic cell growth, increases gemcitabine-induced apoptosis and inhibits invasion.

Related Topics

    loading  Loading Related Articles